Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

SAN FRANCISCO, CA USA (UroToday.com) - While the role of sequential sorafenib (SO) and sunitinib (SU) has been examined retrospectively, no prospective trials have been performed to date.

Dr. Maurice-Stephan Michel presented results from the first prospective, randomized controlled trial of sequential SO/SU versus SU/SO for metastatic RCC. Patients with metastatic RCC with good PS and no prior exposure to cytokines or systemic therapy were randomized to SO/SU (n=182) or SU/SO (n=183). gucancerssympalt thumbThe primary endpoint examined was total PFS from randomization to event during second-line therapy. Baseline characteristics were well balanced between groups. There was no significant difference in total PFS (HR 1.01, p=0.54) or OS between treatment arms (HR 0.997, p=0.49). Median OS was 31.5 vs 30.2 months for SO/SU and SU/SO, respectively. Fewer patients crossed over to receive SO in the SU/SO arm.

The most frequent adverse events for first-line treatment included alopecia (29% SO vs 4% SU), diarrhea (43% SO vs 29% SU), fatigue (21% SO vs 34% SU), hypertension (24% SO vs 24% SU), nausea (18% SO vs 24% SU), and rash (22% SO vs 3% SU). Overall, adverse events were lower during second-line therapy.

In conclusion, both drugs provided overall benefit regardless of sequence, with no significant difference in total PFS and OS between the two sequential treatments. More patients reached second-line therapy in the SO/SU arm.

Highlights of a presentation by Maurice-Stephan Michel, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Rhode Island Hospital, Providence, RI USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Calendar
Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor